Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03084796 · ClinicalTrials.gov registry record · Phase 2
A 6-week Dose Ranging Study of CHF 5259 pMDI in Subjects With Chronic Obstructive Pulmonary Disease
A Phase 2 study, sponsored by Chiesi Farmaceutici S.p.A..
- Completed
- Registry status
- Phase 2
- Development phase
- 733
- Enrollment target
NCT03084796 is a Phase 2 study that has completed, run by Chiesi Farmaceutici S.p.A.. The registered enrollment target is 733 participants.
The verdict
NCT03084796, a Phase 2 study, has completed, sponsored by Chiesi Farmaceutici S.p.A..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 733 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the dose-response of different doses of CHF 5259 pMDI on lung function and other clinical outcomes, to identify the optimal dose(s) in terms of benefit/ risk ratio for further development in the target subject population.
Interventions
- DRUG Placebo
- DRUG CHF 5259
- DRUG Tiotropium Bromide 18 µg Inhalation Capsule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 733 participants |
| Start Date | 2017-07-28 |
| Est. Completion | 2018-06-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03084796
The ClinicalTrials.gov registry entry for NCT03084796 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 733 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Chiesi Farmaceutici S.p.A., which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03084796 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03084796 about?
NCT03084796 is a clinical study titled "A 6-week Dose Ranging Study of CHF 5259 pMDI in Subjects With Chronic Obstructive Pulmonary Disease". The purpose of this study is to evaluate the dose-response of different doses of CHF 5259 pMDI on lung function and other clinical outcomes, to identify the optimal dose(s) in terms of benefit/ risk ratio for further development in the target subject population.
What is the current status of trial NCT03084796?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 733 participants. The study started on 2017-07-28. Estimated completion is 2018-06-06.
What interventions are being tested in trial NCT03084796?
The interventions under investigation include: Placebo (DRUG), CHF 5259 (DRUG), Tiotropium Bromide 18 µg Inhalation Capsule (DRUG).
Who is sponsoring clinical trial NCT03084796?
This trial is sponsored by Chiesi Farmaceutici S.p.A., which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.